Immune-checkpoint inhibition for resectable non-small-cell lung cancer — opportunities and challenges
Cancer Types
Targeted Oncology
A Phase Ib Study Assessing the Safety, Tolerability, and Efficacy of the First-in-Class Wee1 Inhibitor Adavosertib (AZD1775) as Monotherapy in Patients with Advanced Solid Tumors
Esmo Open
A phase Ib/II dose expansion study of subcutaneous sasanlimab in patients with locally advanced or metastatic non-small-cell lung cancer and urothelial carcinoma
Journal of Hematology and Oncology
Emerging therapies targeting the delta-like ligand 3 (DLL3) in small cell lung cancer
Breast Cancer Research
XENERA-1: a randomised double-blind Phase II trial of xentuzumab in combination with everolimus and exemestane versus everolimus and exemestane in patients with hormone receptor-positive/HER2-negative metastatic breast cancer and non-visceral disease
Journal of Clinical Oncology
First-in-Human, Phase I Dose-Escalation and Dose-Expansion Study of Trophoblast Cell-Surface Antigen 2-Directed Antibody-Drug Conjugate Datopotamab Deruxtecan in Non-Small-Cell Lung Cancer: TROPION-PanTumor01
Journal of Clinical Oncology
Cancer Treatment Reviews
Novel endocrine therapies: What is next in estrogen receptor positive, HER2 negative breast cancer?
Journal of Clinical Oncology
Tarlatamab, a first-in-class DLL3-targeted bispecific T cell engager, in recurrent small-cell lung cancer: an open-label, phase 1 study
Therapeutics Advances in Medical Oncology
Rationale and trial design of NATALEE: a Phase III trial of adjuvant ribociclib + endocrine therapy versus endocrine therapy alone in patients with HR+/HER2- early breast cancer